Market Overview: Multiple Myeloma   27-page PDF document
$299.00

Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Market Overview: Multiple Myeloma (27-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Multiple Myeloma (PDF)

PDF document 27 Pages

#1 in Oncology $299.00
Explore the comprehensive market overview of multiple myeloma, detailing growth drivers, key therapies, and expert insights. Created by industry specialists.
Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF THIS PDF DOCUMENT

  1. The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025
  2. Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales
  3. Major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025

HEALTHCARE PDF DESCRIPTION

This product (Market Overview: Multiple Myeloma) is a 27-page PDF document, which you can download immediately upon purchase.

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.
Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Multiple Myeloma PDF (PDF) Document, pharmzolgas


$299.00
Explore the comprehensive market overview of multiple myeloma, detailing growth drivers, key therapies, and expert insights. Created by industry specialists.
Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

You must be logged in to contact the author.

Click here to log in Click here register

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"As a young consulting firm, requests for input from clients vary and it's sometimes impossible to provide expert solutions across a broad spectrum of requirements. That was before I discovered Flevy.com.

Through subscription to this invaluable site of a plethora of topics that are key and crucial to consulting, I "

– Nishi Singh, Strategist and MD at NSP Consultants
 
"Flevy is our 'go to' resource for management material, at an affordable cost. The Flevy library is comprehensive and the content deep, and typically provides a great foundation for us to further develop and tailor our own service offer."

– Chris McCann, Founder at Resilient.World
 
"I like your product. I'm frequently designing PowerPoint presentations for my company and your product has given me so many great ideas on the use of charts, layouts, tools, and frameworks. I really think the templates are a valuable asset to the job."

– Roberto Fuentes Martinez, Senior Executive Director at Technology Transformation Advisory
 
"As a consulting firm, we had been creating subject matter training materials for our people and found the excellent materials on Flevy, which saved us 100's of hours of re-creating what already exists on the Flevy materials we purchased."

– Michael Evans, Managing Director at Newport LLC
 
"FlevyPro provides business frameworks from many of the global giants in management consulting that allow you to provide best in class solutions for your clients."

– David Harris, Managing Director at Futures Strategy
 
"Last Sunday morning, I was diligently working on an important presentation for a client and found myself in need of additional content and suitable templates for various types of graphics. Flevy.com proved to be a treasure trove for both content and design at a reasonable price, considering the time I "

– M. E., Chief Commercial Officer, International Logistics Service Provider
 
"My FlevyPro subscription provides me with the most popular frameworks and decks in demand in today’s market. They not only augment my existing consulting and coaching offerings and delivery, but also keep me abreast of the latest trends, inspire new products and service offerings for my practice, and educate me "

– Bill Branson, Founder at Strategic Business Architects
 
"Flevy.com has proven to be an invaluable resource library to our Independent Management Consultancy, supporting and enabling us to better serve our enterprise clients.

The value derived from our [FlevyPro] subscription in terms of the business it has helped to gain far exceeds the investment made, making a subscription a no-brainer for any growing consultancy – or in-house strategy team."

– Dean Carlton, Chief Transformation Officer, Global Village Transformations Pty Ltd.


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Value Chain Analysis Integrated Financial Model

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.